We are on a mission to elevate patient care in breast cancer and beyond.
With nearly 2 million new diagnoses annually, breast cancer is the second most prevalent cancer worldwide. Up to 30% of people diagnosed with breast cancer ultimately develop metastatic disease.
Like many people and families, much of our team has been personally affected by this disease, fueling our collective passion to create more effective, safe, and convenient treatments to help people living with cancer feel better, longer. Meet our team of oncology experts with a track record of bringing disruptive new therapies to market.
Our Team
leadership
board of directors
leadership
board of directors
leadership
Sean P. Bohen, M.D., Ph.D.
Shane Kovacs
Naseem Zojwalla, M.D.
David C. Myles, Ph.D.
Julie Dexter
Sasha Austin, CPA
Yolande Du Toit, MD
Richard Hernandez
Kamesh Kuchimanchi, Ph.D.
Kristin Lanzi
Courtney O'Konek
Gopinath Palanisamy, DVM, Ph.D., DACVP
Mark Shilkrut, M.D., Ph.D.
Kate Swearingen
Margaret Tonda, PharmD
Rachel Wei, Ph.D.
Jim Zhang, Ph.D.
Sean P. Bohen, M.D., Ph.D.
Ian Clark
Cindy Butitta
Scott Garland
Cyrus Harmon, Ph.D.
Sandra J. Horning, M.D., FACP, FASCO
Gorjan Hrustanovic, Ph.D.
Yi Larson, MBA
Andy Rappaport
Graham Walmsley, M.D., Ph.D.